Aiobio아이오바이오

Aiobio's shares have fallen sharply over the past year, and the data pack has no recent financial statements to explain the business's current earnings.

Aiobio, a KONEX-listed maker of dental diagnostic devices using biofluorescence screening, closed at ₩1,999 on 21 October 2026, with a market value of about ₩5.5B. The shares are down 46.2% over one year and sit well above their 52-week low of ₩0, though the low figure looks like a data gap. The data pack contains no annual or trailing financials, valuation multiples or dividend record beyond a 0% yield, so the current earnings position cannot be assessed from it.

What stands out

• The share price is down 10.6% over one month, 2.2% over three months and 46.2% over one year, against a 52-week high of ₩4,510.
• Market value is about ₩5.5B on 2,772,756 listed shares, and the peer group ranges from roughly ₩1.1T to ₩3.0T, so Aiobio is far smaller than its listed peers.
• Trading flows over the last 20 days show net retail selling of about ₩0.2B, with no recorded foreign or institutional net flows, and foreign ownership is steady at 0.3%.
• Recent filings are mostly investor relations events, insider and 5%+ holding reports, an amended annual report for December 2025, and AGM results from March 2026.
• No news headlines were found in the data for the period.

What to watch

• The next filed financial statements, since the data pack holds no annual or trailing financial figures to show revenue or profit trends.
• Whether the amended annual report and audit report filings from April and May 2026 contain any changes that matter to investors.
• Progress of the LINKDENS software trial rollout and overseas market expansion, which the company profile describes but the data does not quantify.